摘要
为了控制抗高血压药物甲磺酸多沙唑嗪产品质量,对制备甲磺酸多沙唑嗪过程中产生的一个未知杂质进行了推测与合成。HPLC、LC-MS、NMR和IR确证所合成的化合物结构即未知杂质1-(4-羟基-6,7-二甲氧基-2-喹唑啉基)-4-(1,4-苯并二恶唑-2-甲酰基)呱嗪。
To perform the quality control of antihypertensive drug-Doxazosine Mesylate an impurity existed in the Doxazosine Mesylate products was synthesized and characterized. The experimental results indicated that the existence of the impurity was related to the hydrolyzation process. This impurity was synthesized and its structure was confirmed using HPLC, LC-MS, NMR, and IR.
作者
陈仕云
何勇
于艳英
彭扶云
高永好
吴宗好
CHEN Shi-yun;HE Yong;YU Yan-ying;PENG Fu-yun;GA;WU Zong-hao(Analytical ＆ Testing Center,Hefei University,Hefei 230601,China;Hefei Huafang Pharmaceutical Science ＆ Technology Co.,Ltd.,Hefei 230088,China)
出处
《精细化工中间体》
CAS
2018年第3期61-64,共4页
Fine Chemical Intermediates
基金
国家重大专项新药创制(2017ZX09201003-006)
关键词
甲磺酸多沙唑嗪
未知杂质
水解
确认
Doxazosine Mesylate
unknown impurity
hydrolyze
confirmation
